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Canine parvovirus (CPV), which causes hemorrhagic 
enteritis in dogs, has 3 antigenic variants: types 2a, 2b, 
and 2c. Molecular method assessment of the distribution 
of the CPV variants in Europe showed that the new variant 
CPV-2c is widespread in Europe and that the viruses are 
distributed in different countries.
C
anine parvovirus type 2 (CPV-2) is a small, nonenvel-
oped DNA virus that emerged suddenly in 1978 as an 
enteric pathogen of dogs. Two antigenic variants, CPV-2a 
and CPV-2b, are now distributed worldwide (1). A third 
CPV variant, ﬁ  rst named Glu-426 mutant and subsequently 
renamed CPV-2c, was detected in Italy in 2000 (2) and 
is now circulating in that country together with types 2a 
and 2b (3–5). The new variant 2c has also been reported in 
Vietnam by Nakamura et al., who developed monoclonal 
antibodies that can identify speciﬁ  cally such a mutant (6) 
and more recently in the United States by Saliki et al. (un-
pub. data) and in South America (7). The antigenic variants 
differ from the original type CPV-2 for a few amino acids 
in the VP2 protein, whereas genetic differences among the 
variants are determined only by residue 426, with types 2a, 
2b, and 2c displaying Asn, Asp, and Glu, respectively (8,9). 
Recently, minor groove binder (MGB) probe assays have 
been established for characterization of CPV strains and ac-
count for the presence of single nucleotide polymorphisms 
in the genome of the different variants (5). Our objective 
was to determine the distribution of the CPV variants in 
different European countries by using the new technology, 
with particular emphasis on the widespread circulation of 
CPV-2c in some areas of Europe.
The Study
A total of 232 fecal samples or CPV isolates were ob-
tained from dogs with diarrhea in Italy (n = 107), Germany 
(n = 37), the United Kingdom (n = 41), Portugal (n = 31), 
Belgium (n = 13), Spain (n = 1), Switzerland (n = 1), and the 
Czech Republic (n = 1). The fecal samples collected in Italy, 
the United Kingdom, Portugal, and Belgium were CPV-posi-
tive according to PCRs performed in local laboratories. Sam-
ples were collected during 2005–2006, with the exception of 
samples from Italy that were collected only in 2006 because 
other studies had assessed the molecular epidemiology of 
CPV in the previous decade (5). All samples from Germany 
consisted of cell-culture–adapted CPV strains isolated from 
dogs with diarrhea in Germany during 1996–2005.
Samples were homogenized (10% w/v) in phosphate-
buffered saline (pH 7.2) and subsequently clariﬁ  ed by cen-
trifuging at 1,500× g for 15 min. Viral DNA was extracted 
from the supernatants of fecal homogenates or from the vi-
ral suspensions by boiling for 10 min and chilling on ice. 
To reduce residual inhibitors of DNA polymerase activity 
to ineffective concentrations, the DNA extracts were dilut-
ed 1:10 in distilled water (10). CPV DNA titers were cal-
culated by using a real-time PCR, based on TaqMan tech-
nology and able to recognize all CPV strains (10), whereas 
characterization of the viral type was obtained by means of 
MGB probe assays speciﬁ  c for types 2a/2b and 2b/2c (5). 
To rule out the presence of CPV strains of vaccine origin, 
which are usually type 2 or less frequently type 2b, we sub-
sequently tested samples recognized as types 2/2a and 2b 
by MGB probe assays that discriminate between vaccine 
and ﬁ  eld strains of CPV (11,12).
All samples that had CPV-positive results from lab-
oratories located in the countries of sample origin were 
conﬁ  rmed by TaqMan assay to contain CPV DNA. CPV 
infection was also demonstrated in the single samples from 
Spain, Switzerland, and the Czech Republic (Figure). In 
Italy, a nearly complete substitution of CPV-2b by CPV-2c 
was noted; CPV-2a strains were found at low frequency, 
which conﬁ  rmed the progressive decrease noted during the 
past 5 years (3–5). In contrast, CPV-2b is still prevalent 
in Germany and Portugal, although CPV-2c is also wide-
spread in these countries. Retrospective analysis of archi-
val samples showed that CPV-2c has been circulating in 
Germany since 1996. An equivalent distribution of types 2a 
and 2b was assessed in the United Kingdom, where a single 
CPV-2c strain was detected. In Portugal, no CPV-2a strain 
was detected, whereas in Belgium all CPVs were type 2a. 
The single samples from Switzerland and the Czech Re-
public were CPV-2a, whereas the sample from Spain was 
CPV-2c. The original type CPV-2 was detected in 1 sample 
from the United Kingdom and 4 from Italy, but the latter 
samples had been collected from dogs shortly after vacci-
nation with a classic type-2–based vaccine (12).
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Conclusions
Despite its DNA genome, CPV possesses a high ge-
netic substitution rate, similar to that observed for RNA 
viruses, which is responsible for continuous antigenic evo-
lution and rapid displacement of old types by new antigenic 
variants (13). CPV-2c, which emerged in Italy in 2000 (2), 
is spreading with high efﬁ  ciency in the dog population of 
Italy and progressively replacing the antigenic variants 2a 
and 2b (3–5). Such a variant has been detected in Vietnam 
also (6), but no information is available on its presence and 
distribution in other European countries, except for a single 
case report from Spain (14).
Our study shows that the new variant 2c is widespread 
in some European countries (Italy, Portugal, and Germany) 
and that it could be detected sporadically in the United 
Kingdom. In contrast with previous studies of CPV-2a in 
Europe, our study showed that CPV-2a is most frequent in 
Belgium, whereas in the United Kingdom, Germany, and 
Italy, it has been overtaken by CPV-2b or CPV-2c. In Por-
tugal, CPV-2a was not detected at all, but types 2b and 2c 
were equally distributed. To our knowledge, this is the ﬁ  rst 
report of the new variant 2c in Portugal, the United King-
dom, and Germany. In Germany, CPV-2c was detected in 
archival samples collected in 1996; thus, it was circulat-
ing in Europe 4 years before its ﬁ  rst ofﬁ  cial report in Italy. 
Such a variable geographic distribution of the CPV variants 
in Europe may be related to different commercial ﬂ  ows of 
dogs imported from foreign countries rather than to differ-
ent vaccination protocols.
The progressive spreading of CPV-2c in the world or, 
less probably, its independent emergence in different coun-
tries, suggests that the Glu-426 mutation provides a certain 
advantage in viral replication. The replacement of CPV-2 
by types 2a and 2b has been associated with increased abil-
ity to bind canine transferrin receptors, although it might 
not rule out the possibility of mutations at residue 426 of 
the VP2 protein being selected also for their antigenic ef-
fects (1). Whether the Glu-426 mutation confers beneﬁ  t in 
receptor-binding activity is of interest. Another question is 
whether the CPV vaccines currently used provide full pro-
tection against the new variant or whether they should be 
replaced by homologous vaccines.
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